New discovery sheds light on the genetic basis of a rare skeletal disorder

No­var­tis’ re­or­ga­ni­za­tion is pay­ing off, CEO Vas Narasimhan told in­vestors at an event Thurs­day in Lon­don. The com­pa­ny raised its sales guid­ance through 2028 and

Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings